Greater Baltimore Medical Center

Summary

Greater Baltimore Medical Center is a medical facility located in Towson, Maryland. This center is recognized for care of Breast Cancer, Ovarian Cancer, Lung Cancer, Breast cancer, Fallopian Tube Cancer and other specialties. Greater Baltimore Medical Center is involved with conducting 237 clinical trials across 343 conditions. There are 13 research doctors associated with this hospital, such as Mei Tang, Gang Chen, Kruti Patel, and Paul Celano.

Top PIs

Clinical Trials running at Greater Baltimore Medical Center

Lung Cancer

Breast Cancer

Bladder Cancer

Laryngeal Cancer

Bladder Carcinoma

Oropharyngeal Carcinoma

Throat Cancer

Breast cancer

Cancer

Lip and Oral Cavity Cancer

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Osimertinib +/- Chemotherapy

for Lung Cancer

The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.

Recruiting

1 award

N/A

8 criteria